PYA Waltman Capital LLC Has $6.42 Million Stake in Amgen Inc. $AMGN

Key Points

• PYA Waltman Capital increased its Amgen stake by 29% in the second quarter, holding 17,735 shares valued at approximately $6.42 million. Institutional investors collectively own 76.5% of Amgen’s stock.
• Amgen reported quarterly EPS of $6.29 and revenue of $10.05 billion, beating analyst estimates, while revenue rose 9.5% year over year. The company also declared a quarterly dividend of $2.52 per share, equivalent to a 2.3% annual yield.
• Amgen’s outlook is supported by promising Repatha cardiovascular data and raised earnings expectations, but risks include the UK suspension of Tavneos for new patients, insider selling, and a consensus analyst rating of “Hold.”

PYA Waltman Capital LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 29.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 17,735 shares of the medical research company's stock after purchasing an additional 3,983 shares during the period. Amgen accounts for approximately 1.6% of PYA Waltman Capital LLC's investment portfolio, making the stock its 16th biggest position. PYA Waltman Capital LLC's holdings in Amgen were worth $6,422,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC lifted its stake in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC lifted its position in shares of Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock worth $331,000 after purchasing an additional 114 shares during the period. Schnieders Capital Management LLC. boosted its stake in shares of Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock valued at $7,220,000 after purchasing an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC increased its position in shares of Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company's stock worth $1,141,000 after buying an additional 416 shares during the period. Finally, Ieq Capital LLC raised its stake in Amgen by 5.1% during the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company's stock worth $15,120,000 after buying an additional 2,611 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $438.12 on Wednesday. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $447.03. The stock's 50 day moving average is $392.17 and its 200-day moving average is $365.59. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a market capitalization of $236.86 billion, a price-to-earnings ratio of 27.23, a PEG ratio of 3.10 and a beta of 0.43.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen's revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts forecast that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen's payout ratio is presently 62.65%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha delivers potentially market-expanding cardiovascular data. Amgen reported that Repatha (evolocumab) reduced the risk of death by 20% in more than 12,000 high-risk patients who had not previously suffered a heart attack or stroke. The Phase 3 VESALIUS-CV findings could support broader use of the cholesterol drug, increase physician adoption and strengthen one of Amgen’s key revenue drivers. Amgen Repatha clinical results
• Positive Sentiment: Analysts are raising earnings expectations. Erste Group Bank increased its FY2027 EPS forecast to $24.43 from $23.50, above the broader consensus estimate of $22.97. The revision follows Amgen’s recent quarterly earnings and revenue beat, along with higher full-year guidance, reinforcing the company’s favorable earnings momentum. Erste Group Bank earnings forecast
• Positive Sentiment: Investor attention is increasing around Amgen’s cardiovascular opportunity. Jim Cramer highlighted Repatha as a largely overlooked drug that could address a very large market, potentially comparable in importance to major obesity-drug markets over time. While this is commentary rather than a fundamental forecast, it adds to the bullish narrative surrounding Repatha. Jim Cramer on Amgen’s Repatha opportunity
• Neutral Sentiment: Relative performance remains favorable, but valuation is being debated. Reports note that AMGN has outperformed the broader market and other general drug manufacturers, while analysts remain moderately bullish. However, the stock’s strong run and elevated valuation could limit additional upside unless earnings and product growth continue to accelerate. Amgen stock performance compared with drug manufacturers
• Negative Sentiment: UK regulators suspended Tavneos for new patients. Britain’s medicines regulator cited unreliable data from the main study supporting approval of the rare-disease drug and suspended its use and sale for new patients. The action creates regulatory, reputational and potential revenue risks, although Tavneos is smaller than Amgen’s major commercial products. UK regulator Tavneos suspension

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company's stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company's stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 in the last 90 days. 0.85% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of recent analyst reports. Morgan Stanley reiterated an "overweight" rating and set a $362.00 price target on shares of Amgen in a report on Wednesday, August 19th. Wall Street Zen raised Amgen from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Piper Sandler lifted their target price on Amgen from $427.00 to $457.00 and gave the stock an "overweight" rating in a report on Thursday, August 20th. Erste Group Bank restated a "hold" rating on shares of Amgen in a report on Tuesday, May 5th. Finally, Scotiabank lifted their price objective on shares of Amgen from $385.00 to $450.00 and gave the company an "outperform" rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Amgen has a consensus rating of "Hold" and a consensus price target of $380.43.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source